Innovation, Progress,

and the Future
are Vivozon's Values

Introduction

CEO
Doo-hyun Lee
Name
Vivozon
Est.
1st June 2008
Business
Feild
Medical and pharmaceutical R&D company including pharmaceutical (new drug) R&D and biological product manufacturing

Vivozon is a global innovative drug development company established in 2008. We built an efficacy-based new drug discovery system that is clearly distinct from the existing new drug development paradigm, and discovered the non- narcotic analgesic opiranserin (VVZ-149) in less than a year. Opiranserin, which is currently undergoing global phase 3 clinical trials as a single-dose injectable for treating postoperative pain, will be expanded to various indications such as neuropathic pain and cancer pain by multiple administration routes. Vivozon boldly invests in R&D and education, expanding its pipeline to address central nervous system diseases such as addiction, schizophrenia, depression, and Parkinson’s disease.

The endless possibilities of Vivozon

An innovative new drug development company specialized in pain and central nervous system diseases,
the blue ocean in the pharmaceutical industry

High potential market for
huge unmet medical needs

Biggest market following cancer therapeutics

High barriers for successful development during the past 20 years of failure in pain therapeutics

Opioid crisis

Cultivation of candidate substances
with promising clinical success based
on efficacy-based screening

Leading multi-target drug development platform technology

Tissue-level efficacy testing method applicable to initial screening

Efficacy studies in animals with clinical trial criteria conformity (randomized, blind, positive control and PK/PD correlation)

Ripple effects for breakthrough innovation
upon successful achievement

VVZ-149 (Opiranserin)
- First-in-class non-narcotic analgesics
- Global phase 3 clinical trial for injection, FDA Fast Track designation
- PPreparation of phase 2 clinical trial for external use

Superior follow-up drug R&D pipeline

Innovation

High potential market for
huge unmet medical needs

Biggest market following cancer therapeutics

High barriers for successful development during the past 20 years of failure in pain therapeutics

Opioid crisis

Paradigm Shift

Cultivation of candidate substances
with promising clinical success based
on efficacy-based screening

Leading multi-target drug development platform technology

Tissue-level efficacy testing method applicable to initial screening

Efficacy studies in animals with clinical trial criteria conformity (randomized, blind, positive control and PK/PD correlation)

Tremendous Impact

Ripple effects for breakthrough innovation
upon successful achievement

VVZ-149 (Opiranserin)
- First-in-class non-narcotic analgesics
- Global phase 3 clinical trial for injection, FDA Fast Track designation
- PPreparation of phase 2 clinical trial for external use

Superior follow-up drug R&D pipeline

A leap forward as a global innovative
new drug development company

Vivozon moves
당당하게 꿈을 향해 끊임없이 행복하게
to the future for your happiness

Despite challenges and barriers for successful drug development, we boldly jump into the development of new drugs that are essential to the health and happiness of people around the world. Vivozon makes new drugs that change the world.